Apple Inc. (NASDAQ:AAPL) is up 0.41% in pre-market trading to $112.90 after Rob Cihra of Sterne Agee initiated coverage on the technology company with a Buy rating and a $150 price target. The analyst believes Apple still has room for growth since many users have not upgraded to the iPhone 6 yet. He explains, “Apple can keep pushing out the law-of-large numbers as it creates its own growth and captures value from others by engineering innovative hardware+software+services in a vertically-integrated model.” Cihra adds that despite market worries in China, iPhones in the country jumped 87% year-over-year. Apple is now benefitting from “an installed base” in China, which will be on track to upgrade to newer models. According to the 37 analysts polled by TipRanks over the last 3 months, 27 are bullish on Apple, 9 are staying on the sidelines, and 1 is bearish.

Click here to see Rob Cihra’s past ratings and performance history.

GoPro Inc (NASDAQ:GPRO) is up 1.38% in pre-market trading to $30.08 after Rob Cihra of Sterne Agee initiated coverage on the action camera company with a Buy rating and a $45 price target. Cihra explains that many “one-function products” get absorbed by phones and thus become obsolete. GoPro, he assures, has a unique defense in that “it’s expressly designed for situations/environments where users wouldn’t want to risk wrecking their phone.” He warns that growth may pause in the second half of this year, but 2016 “sets up as a strong new product year driven by HERO5 and launch of GPRO’s first consumer quad-copter.” The analyst added that the company needs to prove that it is more than a fad, concluding, “It is nevertheless critical for GPRO to keep trying to build out whatever competitive moat it can in value-added software and associated network effects.” As of this writing, 17 analysts have rated GoPro on TipRanks in the last 3 months. Of these analysts, 13 are bullish on the company and 4 are bearish.

Click here to see Rob Cihra’s past ratings and performance history.

Yahoo! Inc. (NASDAQ:YHOO) shares are up 3.62% in pre-market trading up to $28.60 after the company announced that it will go ahead and spin off its Alibaba shares without waiting for a go-ahead from the IRS, meaning that the transaction may not be tax-free as hoped. Earlier this month, the IRS denied Yahoo a private letter ruling. Yahoo’s insistence on completing the transaction in the fourth quarter may result in a multi-billion tax bill. Amid the announcement, Neil Doshi of Mizuho Securities reiterated a Buy rating on the stock, noting, “We believe the likelihood of a positive tax outcome for the company could be more likely now… In our opinion, the IRS is maintaining the status quo on this issue, and with no changes to guidance on this matter, we believe that Yahoo should be able to complete this transaction in a tax-free manner.” As of this writing, 24 analysts polled by TipRanks have rated Yahoo in the last 3 months. Of those analysts, 19 are bullish on the stock while 5 are staying on the sidelines. The average 12-month price target between the 24 analysts is $46.05, marking a 67% potential upside from where the stock last closed.

Click here to see Neil Doshi’s past ratings and performance history.

Novavax, Inc. (NASDAQ:NVAX) soared more than 10% in pre-market trading up to $8.99 after the biopharmaceutical company announced positive data from its Phase 2 trial of respiratory syncytial virus, or RSV F Vaccine tested to protect infants via maternal immunization. The study tested the safety and efficacy of the vaccine in 50 healthy pregnant women and the impact of the child through its first six months of life. At the same time, the company announced that it received an $89 million grant from the Bill and Melinda Gates Foundation to support the development of this vaccine in pregnant women. RSV is a common cause of lower respiratory infections, which can become severe in young children. It is the leading cause of hospitalization for infants in the U.S. and kills about 160,000 annually. According to the 2 analysts polled by TipRanks in the last 3 months, both are bullish on Novavax with an average 12-month price target of $15.50, marking a 90% potential upside from where the stock last closed.